The Cigna Group (CI)

NYSE: CI · USD

$295

-3.37 (-1.1%)· Recorded snapshot

Engelse bronNL

Engelse bron wordt weergegeven terwijl we vertalen

Dit rapport is nog niet vertaald. Vernieuw over een paar minuten zodra de vertaalwachtrij is bijgewerkt.

StockMarketAgent Research · Analyzed 2026-10-22

Our latest published analysis: CI rated Strong Buy

The Cigna Group's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$478 / share

Potential value

$825 / share

Upside to FV

+57.1%

from $295

Moat

7.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$80.4B
Revenue (ttm)	282.4B
Net income (ttm)	6.4B
EPS (ttm)	$24.2
Shares out	264.2M
P/E (trailing)	12.2x
P/E (forward)	8.3x
Dividend	$6.24 (2.12%)
Volume	736,939
Beta	0.30

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 282.4B
Net income (ttm): 6.4B
EPS (ttm): $24.2
P/E (trailing): 12.2x
P/E (forward): 8.3x
Market cap: $80.4B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$174.07B	$180.52B	$195.27B	$247.12B	$274.90B	+12.1%
Gross profit	$22.95B	$23.50B	$25.18B	$25.96B	$25.99B	+3.2%
Operating income	$7.94B	$8.45B	$8.54B	$9.42B	$9.20B	+3.7%
Net income	$5.37B	$6.70B	$5.16B	$3.43B	$5.96B	+2.6%
EPS (diluted)	$15.75	$21.41	$17.39	$12.12	$22.18	+8.9%
EBITDA	$11.09B	$11.52B	$12.07B	$12.47B	$11.75B	+1.5%
R&D	—	—	—	—	—	—
SG&A	$13.01B	$13.17B	$14.82B	$14.84B	$14.62B	+3.0%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
AAPL	Apple Inc.	5T	39.4x	10.8x	101.6%	+6.1%	+28.5%	Verkopen
ABNB	Airbnb, Inc.	97.8B	37.5x	7.4x	16.8%	+24.4%	+28.5%	Verkopen
ADBE	Adobe Inc.	97.1B	13.9x	3.7x	57.2%	+11.5%	-30.7%	Sterk kopen
ABBV	AbbVie Inc.	505.6B	80.8x	7.9x	17.7%	+3.7%	+29.1%	Verkopen
ABT	Abbott Laboratories	177.6B	38.2x	3.7x	7.2%	+2.7%	-17.2%	Verminderen
ALGN	Align Technology Inc.	10.9B	26.6x	2.6x	17.2%	+3.6%	+11.6%	Verminderen

Base and Bull scenarios

Bull20%

Price target

$825.00

+171.1% from spot

Under the bull scenario, biosimilar adoption accelerates beyond management expectations, expanding specialty pharmacy margins. Commercial employer enrollment grows in Middle and Select markets, while transparent Evernorth Signature contracts scale rapidly with early adopters. Enterprise earnings compound at the upper end of management's 10-14% long-term target, driving valuation multiple expansion toward the high end of our fair value range ($825.00).

Evernorth Specialty & Care Services pre-tax income expands above 15% annually driven by rapid biosimilar uptake.
Cigna Healthcare medical care ratio remains disciplined near the favorable end of guided ranges, supported by commercial pricing power.
Share repurchases retire 2.0% of diluted shares annually, driving EPS growth of 12-14%.

Base55%

Price target

$478.08

+57.1% from spot

The base case represents the modal expected trajectory, delivering an 8.5% EPS compounding path. Consensus FY2026 EPS of $30.51 and FY2027 EPS of $33.48 are met as Evernorth specialty volume offsets retail pharmacy pricing concessions. Re-rating to mid fair value of $478.08 reflects steady execution and capital return.

Consolidated revenue grows at 4.0% to 4.5% annually across FY2026-FY2027 in line with consensus ($287.45B and $299.16B),.
Consolidated operating margin stabilizes around 3.35% to 3.55%.
Cigna Healthcare MCR tracks within full-year guidance of 83.7% to 84.7%.
Diluted share count declines 1.5% to 1.8% annually via free-cash-flow-funded buybacks.

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($478.08). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
6.5%	$517	$531	$546	$565	$586
7.0%	$486	$496	$508	$522	$538
7.5%	$460	$469	$478	$489	$500
8.0%	$439	$446	$453	$461	$471
8.5%	$420	$426	$432	$439	$446

Scorecard

Published factor rows and weighted composite

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E8.3

P25 n/aP50 n/aP75 n/a

Trailing P/E12.7

P25 n/aP50 n/aP75 n/a

ROE16.8

P25 n/aP50 n/aP75 n/a

ROIC13.4

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CI indicators

Market & fundamental data

Available fields

280

Groups with data

Currency

USD

Showing 280 of 280 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001739940
Company name	The Cigna Group
Country	United States
Country code	US
CUSIP number	125523100
Earnings date	2026-11-05
Earnings time	bmo
Employees	67,700
Employees change	-5,800
Employees growth	-7.89%
Enterprise value	$102.5B
Exchange	NYSE
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1792
In index	SP500
Industry	Healthcare Plans
Is primary listing	Yes
Is SPAC	No
ISIN number	US1255231003
Last 10-K release date	2026-02-26
Last earnings date	2026-07-30
Last refreshed	2026-10-28
Last stock split date	2007-06-05
Last stock split type	Forward
Market cap	$77.9B
Market cap category	Large-Cap
Next earnings date	2026-11-05
Options	Yes
Price	$294.90
Price currency	USD
Sector	Healthcare
SIC code	6324
Stock price date	2026-10-28
Symbol	CI
U.S. state	Connecticut
Website	https://www.thecignagroup.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	9.37x
Average P/E ratio (10Y)	16.32x
Average P/E ratio (3Y)	18.63x
Average P/E ratio (5Y)	16.34x
Earnings yield	8.2%
EV/Earnings	16.11x
EV/EBIT	9.38x
EV/EBITDA	8.1x
EV/FCF	11.34x
EV/Sales	0.37x
FCF / EV yield	8.82%
FCF yield	11.57%
Forward EV/Sales	0.35x
Forward P/E	9.26x
Forward P/S	0.27x
Graham number	296.55341
Graham upside	-0.48%
Industry forward P/E	15.03x
Industry P/E	21.44x
Lynch fair value	$120.92
Lynch upside	-59.42%
P/B ratio	1.85x
P/E ratio	12.19x
P/FCF ratio	8.64x
P/OCF ratio	7.66x
P/S ratio	0.28x
PEG ratio	0.89x
Price/EBITDA ratio	6.17x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	3.9%
EBITDA margin	4.52%
Effective tax rate	19.17%
FCF margin	3.23%
Gross margin	9.14%
Operating margin	3.9%
Pretax margin	3.06%
Profit margin	2.27%
Profit per employee	$94,771
Profitable quarters	9
Profitable years	23
Revenue per employee	$4.2M
ROA	4.46%
ROA (5Y)	3.74%
ROCE	10.86%
ROE	16.76%
ROE (5Y)	12.28%
ROIC	13.39%
ROIC (5Y)	10.87%
Tax / revenue	0.59%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	32.61%
EPS growth (Q)	10.16%
EPS growth (QoQ)	0.48%
EPS growth 10Y	12.11%
EPS growth 3Y	3.06%
EPS growth 5Y	1.12%
EPS growth quarters	2
EPS growth years	1
FCF growth	131.06%
FCF growth 3Y	-7.23%
FCF growth 5Y	13.14%
Gross profit growth	-0.13%
Gross profit growth (Q)	6.07%
Gross profit growth 3Y	3.06%
Gross profit growth 5Y	2.25%
Net income growth	27.86%
Net income growth (Q)	8.36%
Net income growth (QoQ)	0.36%
Net income growth 3Y	-1.32%
Net income growth 5Y	-4.67%
Net income growth quarters	2
Net income growth years	1
OCF growth	94.2%
OCF growth 10Y	13.04%
OCF growth 3Y	-7.3%
OCF growth 5Y	11.42%
Operating income growth	12.72%
Operating income growth (Q)	15.72%
Operating income growth 3Y	10.7%
Operating income growth 5Y	7.44%
Revenue growth	7.77%
Revenue growth (Q)	6.68%
Revenue growth (QoQ)	4.63%
Revenue growth 10Y	21.97%
Revenue growth 3Y	14.9%
Revenue growth 5Y	11.11%
Revenue growth quarters	66
Revenue growth years	16

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.2B
Depreciation and amortization	$1.7B
EBIT	$11B
EBITDA	$12.8B
EPS	$24.18
FCF per share	$34.49
Financing cash flow	$-2.3B
Free cash flow	$9.1B
Gross profit	$25.8B
Income taxes	$1.7B
Investing cash flow	$-5.9B
Net borrowing	$1.1B
Net cash flow	$2B
Net income	$6.4B
Operating income	$11B
Revenue	$282.4B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	2.81
Book value per share	$161.62
Debt / EBITDA	2.5
Debt / equity	0.74
Debt / FCF	3.5
Goodwill	$45.5B
Interest coverage	7.78
Long-term assets	$110.1B
Long-term liabilities	$58.6B
Net cash (debt)	$-24.6B
Net cash / market cap	-31.27%
Net debt / EBITDA	1.93
Net debt / equity	0.57
Net debt / FCF	2.7
Piotroski F-Score	6
Property, plant and equipment	$3.7B
Shareholders' equity	$42.9B
Tangible book value	$-29.8B
Tangible book value per share	$-113.18
Total assets	$157.1B
Total cash	$7.3B
Total debt	$31.9B
Total liabilities	$114.2B
WACC	5.23%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.83
Current assets	$47B
Current liabilities	$55.6B
Current ratio	0.85
Inventory turnover	43.44
Net working capital	$-13B
Quick ratio	0.69
Working capital	$-8.6B
Working capital turnover	-27.38

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	3.55%
Dividend growth	4.38%
Dividend growth (10Y)	65.56%
Dividend growth (3Y)	8.77%
Dividend growth (5Y)	15.59%
Dividend growth years	5
Dividend payment date	2026-09-23
Dividend payment years	45
Dividend payout frequency	Quarterly
Dividend per share	$6.24
Dividend yield	2.12%
Ex-dividend date	2026-09-08
FCF payout ratio	18.09%
Last dividend	$1.56
Payout ratio	25.8%
Shareholder yield	5.64%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	139.48%
10Y return CAGR	10.3%
10Y total return	166.46%
150-day SMA	$282.82
15Y price change	522.12%
15Y return CAGR	13.79%
15Y total return	594.1%
1D price change	-1.13%
1M price change	8.34%
1M total return	8.34%
1W price change	-3.88%
1W total return	-3.88%
1Y price change	-4.68%
1Y return CAGR	-2.52%
1Y total return	-2.52%
20-day SMA	$290.69
200-day SMA	$281.38
20Y price change	647.97%
20Y return CAGR	11.23%
20Y total return	740.28%
3M price change	1.27%
3M total return	1.83%
3Y price change	-2.82%
3Y return CAGR	0.99%
3Y total return	3%
50-day SMA	$283.01
50-day SMA vs 200-day SMA	50over200
52-week high	$316.27
52-week high date	2026-10-22
52-week low	$239.51
52-week low date	2025-11-03
5Y price change	38.1%
5Y return CAGR	8.67%
5Y total return	51.55%
6M price change	4.29%
6M total return	5.48%
All-time high	$370.83
All-time high date	2024-09-16
All-time low	$3.00
All-time low date	1984-07-19
Average true range (ATR)	$7.57
Average volume	1.4M
Beta (1Y)	-0.09
Beta (2Y)	0.18
Beta (5Y)	0.3
Change from 52-week high	-6.76%
Change from 52-week low	23.13%
Change from all-time high	-20.53%
Change from all-time low	9,723.33%
Change from open	-0.4%
Day's gap	-0.74%
Dollar volume	$217.3M
High price	$299.24
Low price	$294.13
Monthly RSI	51.33
Open price	$296.08
Position in 52-week range	15.07%
Premarket change	-0.01%
Premarket close	$298.28
Premarket price	$298.25
Previous close	$298.28
Price vs 150-day SMA	4.2%
Price vs 20-day SMA	1.38%
Price vs 200-day SMA	4.73%
Price vs 50-day SMA	4.13%
Relative volume	0.51
RSI	52.97
Sharpe ratio	-0.03
Sharpe ratio (3Y)	0.06
Sharpe ratio (5Y)	0.29
Sortino ratio	0.12
Sortino ratio (3Y)	0.27
Sortino ratio (5Y)	0.6
Volume	736.9K
Weekly RSI	55.25
YTD price change	7.07%
YTD total return	8.89%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	262.9M
Float percentage	99.5%
Shares change (QoQ)	-0.02%
Shares change (YoY)	-3.55%
Shares held by insiders	0.38%
Shares held by institutions	92.59%
Shares outstanding	264.2M
Short % of float	2.64%
Short % of shares	2.63%
Short ratio	4.3 days

Deeper analysis on CI

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Scorecard

Quote this valuation with its source: Fair value, Potential value and the price at analysis.

Frequently asked questions

About this CI report

What is the latest published CI stock rating?

The Cigna Group is shown with Strong Buy in the latest published report, analyzed 2026-10-22. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CI analysis?

The full latest published report, analyzed 2026-10-22, lives at /stocks/CI/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for CI?

The latest published report analyzed 2026-10-22 gives CI a fair value of USD 478 and a potential value of USD 825. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the CI page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-22). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

Strong BuyCI · Fair value $478+57.1%

Read full analysis →

The Cigna Group (CI)

Our latest published analysis: CI rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · CI

Valuation

Profitability

Balance sheet

Trading

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

All CI indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CI

Frequently asked questions

Ratinggeschiedenis

Category	Score	Reading
Valuation	8.5
Management	9.5
Balance Sheet	4.0
Profitability	6.0
Revenue Growth	6.0
Risk Assessment	6.0
Competitive Moat	7.5
Earnings Quality	8.0
Capital Efficiency	5.5